Hans Schambye
Chief Executive Officer chez GALECTO, INC.
Fortune : 40 894 $ au 31/03/2024
Provenance du réseau au premier degré de Hans Schambye
| Entité | Type d'entité | Industrie | |
|---|---|---|---|
| Public Company | Pharmaceuticals: Major | 22 | |
Maxygen, Inc.
 Maxygen, Inc. Miscellaneous Commercial ServicesCommercial Services Maxygen, Inc. is a biotechnology company. It is focused on the potential further development of its MAXY-G34 product, a next-generation pegylated, granulocyte colony stimulating factor, G-CSF, for the treatment of chemotherapy induced neutropenia and acute radiation syndrome. G-CSF is a natural protein that functions by stimulating the body's bone marrow to produce more white blood cells. The company was founded on May 7, 1996 and is headquartered in San Mateo, CA.
18
| Private Company | Miscellaneous Commercial Services | 18 |
Galecto Biotech ApS
 Galecto Biotech ApS Pharmaceuticals: MajorHealth Technology Galecto Biotech ApS provides galectin modulators for the treatment of severe diseases, including fibrosis and cancer. Its products include galectin-3 inhibitors, fibrosis and literature. The company was founded by Tariq Sethi, Hans Thalsgard Schambye, Ulf Jorgen Nilsson, and Hakon Leffler in 2011 and is headquartered in Copenhagen, Denmark.
17
| Subsidiary | Pharmaceuticals: Major | 17 |
Dansk Biotek
 Dansk Biotek Miscellaneous Commercial ServicesCommercial Services Dansk Biotek is an industry association for biotech companies with promoting the biotechnological research, development and production in taking care of corporate interests in this regard, both nationally and internationally. The company was founded in 1987 and is headquartered in Copenhagen, Denmark.
10
| Private Company | Miscellaneous Commercial Services | 10 |
Profound Pharma AS
 Profound Pharma AS Pharmaceuticals: MajorHealth Technology Profound Pharma AS provides pharmaceutical products. The Danish company was founded by Jan Møller Mikkelsen, Anders H. Pedersen, Hans Thalsgård Schambye. Profound Pharma was acquired by Maxygen, Inc. on August 10, 2000 for $69.46 million.
4
| Extinct | Pharmaceuticals: Major | 4 |
Recepticon ApS
 Recepticon ApS Pharmaceuticals: MajorHealth Technology ReceptIcon is a biotech company based on the identification of novel receptors in the kidney that are responsible for renal uptake and nephrotoxity of therapeutic drugs. The company is focused on the development of receptor antagonists that prevent accumulation of therapeutics in the kidney. Such antagonists can be used as active pharmaceutical ingredients for reformulation of marketed nephrotoxic drugs thereby precluding their toxic side effects.
1
| Extinct | Pharmaceuticals: Major | 1 |
Graphique Sociétés connectées au second degré
Relation dans plusieurs entreprises
Sociétés connectées à Hans Schambye via son réseau personnel
| Société | Secteur | Personnes liées | Poste principal |
|---|---|---|---|
Genentech, Inc.
 Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Biotechnology | Chief Tech/Sci/R&D Officer Corporate Officer/Principal | |
| ARENA PHARMACEUTICALS | Pharmaceuticals: Major | Chief Executive Officer Director/Board Member | |
| NOVO NORDISK A/S | Pharmaceuticals: Major | Corporate Officer/Principal Chief Tech/Sci/R&D Officer Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal General Counsel Corporate Officer/Principal | |
| CYMABAY THERAPEUTICS, INC. | Biotechnology | Director/Board Member General Counsel | |
| INTERCEPT PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Director/Board Member Chief Tech/Sci/R&D Officer | |
Harvard University
 Harvard University Other Consumer ServicesConsumer Services Harvard University engages in the provision of teaching and research. It has twelve degree-granting Schools in addition to the Radcliffe Institute for Advanced Study, offering a global education. The university was founded in 1636 and is headquartered in Cambridge, MA. | College/University | Doctorate Degree Graduate Degree | |
| Stanford University | College/University | Corporate Officer/Principal Graduate Degree Masters Business Admin | |
Novo Holdings AS (Denmark)
 Novo Holdings AS (Denmark) MiscellaneousMiscellaneous Novo Holding A/S provides financial investments and manages the Novo Nordisk Foundation?s assets. It offers seed and venture capital to development stage companies and takes ownership positions in companies within life science and biotechnology. The company was founded on September 8, 1999 and is headquartered in Hellerup, Denmark. | Miscellaneous | Corporate Officer/Principal Chief Investment Officer Director/Board Member | |
| BIOPORTO A/S | Medical Specialties | Director/Board Member Director/Board Member | |
| Karolinska Institutet | College/University | Corporate Officer/Principal Doctorate Degree | |
| The University of Edinburgh | College/University | Masters Business Admin Corporate Officer/Principal | |
| Yale University | College/University | Undergraduate Degree Doctorate Degree Graduate Degree | |
| INSEAD | College/University | Masters Business Admin Masters Business Admin | |
| University of California, Berkeley | College/University | Graduate Degree Graduate Degree Masters Business Admin | |
University of Minnesota
 University of Minnesota Other Consumer ServicesConsumer Services Digi-Key Corp. distributes electronic components. It also distributes semiconductors, discrete, electromechanical parts. Its products include audio products, batteries, cable assemblies, capacitors, computer & video accessories, connectors, crystals & oscillators, discrete semiconductor products and many more. The company was founded by Ronald A. Stordahl in 1972 and is headquartered in Thief River Falls, MN. | College/University | Undergraduate Degree Corporate Officer/Principal | |
| The University of California, San Francisco | College/University | Doctorate Degree Corporate Officer/Principal | |
| ZEALAND PHARMA A/S | Pharmaceuticals: Major | Director of Finance/CFO Chief Executive Officer Chief Executive Officer | |
| Technical University of Denmark | College/University | Graduate Degree Graduate Degree Doctorate Degree Undergraduate Degree Graduate Degree Doctorate Degree Graduate Degree | |
| University of Lund | College/University | Corporate Officer/Principal Doctorate Degree Doctorate Degree | |
| University of Copenhagen | College/University | Graduate Degree Doctorate Degree Corporate Officer/Principal Undergraduate Degree Doctorate Degree Doctorate Degree | |
Takeda A/S
 Takeda A/S Financial ConglomeratesFinance Takeda A/S engages in holding or owning of securities in other companies other than banks. The company was founded on January 4, 2005 and is headquartered in Taastrup, Denmark. | Financial Conglomerates | Corporate Officer/Principal Chief Tech/Sci/R&D Officer | |
| Freie Universität Berlin | College/University | Doctorate Degree Doctorate Degree | |
| University of Southern Denmark | College/University | Undergraduate Degree Undergraduate Degree | |
Evolva SA
 Evolva SA Miscellaneous Commercial ServicesCommercial Services Evolva SA is a Swiss-headquartered, international pharmaceutical biotech company focused on the discovery and development of drugs based on its distinctive and proprietary genetic chemistry platform. The company was founded in Switzerland in 2004 based on US/Danish technology. Evolva is headquartered in Allschwil/Basel with operations in Denmark, India and the USA. The Company has raised CHF 38.2 million of equity to date and employs 75 persons of whom 30 are based in Allschwil. The firm's strategy and business approach is based on five pillars that offer a sustainable development path for creating a successful company, which include Building a balanced portfolio. Evolva focuses on orally available small molecules in the belief that they are more convenient for patients and more cost-effective both from manufacture and administration points of view for the society, focus on differentiated pharmaceutical products with major benefits. Focusing on cardiovascular/renal and infectious diseases. Together they cause more than 50% of all deaths worldwide. Most of the top 20 pharmaceutical companies are active in both sectors, and all are active in one of the two sectors - hence widening Evolva's opportunities to partner. Building technology platform as the source of this differentiation. Evolva finds different structures with different properties from those found by the 99% of the industry that focuses on synthetic chemistry or proteins. Openness to unusual markets. The biotech business model has changed. As well as the established markets new opportunities arise in emerging countries such as India and China, and in adjacent sectors such as treatments against potential bio-terrorist and bio-warfare agents and the production of pharmaceutical and industrial chemical intermediates. Cost-effective implementation. Evolva places different functions around the globe according to where local conditions best suit. This approach both reduces Evolva's cost base and increases access to revenues, partners and talent. Evolva sees revenues and partners as important because they provide additional flexibility, resources and talent. Also, they provide important opportunities to better understand, and better meet, the needs of current and future customers. | Miscellaneous Commercial Services | Corporate Officer/Principal Director of Finance/CFO | |
Symphogen A/S
 Symphogen A/S Pharmaceuticals: MajorHealth Technology Symphogen A/S provides antibody therapeutics for the treatment of cancers. It offers oncology products and creates selected antibody mixtures that address multiple oncology targets in a single drug product. The firm’s pipeline is fueled by its technology suite capable of identifying, selecting, manufacturing, and characterizing optimal antibody mixtures. The company was founded by Kirsten Aarup Drejer, Thomas Feldthus, Eigil Bjerl Nielsen, Anker Gunvald Lundemose, Kim Arthur Hueg, and John Soerensen Haurum in 2000 and is headquartered in Ballerup, Denmark. | Pharmaceuticals: Major | Director/Board Member General Counsel | |
OrbiMed Advisors Private Equity
 OrbiMed Advisors Private Equity Investment ManagersFinance OrbiMed Advisors Private Equity (OrbiMed Advisors Private Equity) is a private equity and venture capital subsidiary of Orbimed Advisors LLC founded in 1993 by Samuel D. Isaly. The firm is headquartered in New York and it has additional offices in San Francisco, Mumbai, Shanghai, Herzliya, Hong Kong and London. | Investment Managers | Private Equity Investor Private Equity Investor | |
| ASCENDIS PHARMA A/S | Pharmaceuticals: Major | Founder Chief Operating Officer Corporate Officer/Principal Corporate Officer/Principal | |
| XYLO TECHNOLOGIES LTD | Medical Specialties | Director/Board Member | |
Lundonia Biotech AB
 Lundonia Biotech AB Miscellaneous Commercial ServicesCommercial Services Lundonia Biotech AB provides academic and industrial research and development services with diagnostic tools. Its products include GlycoWell microplates, affinity matrices, fluorophorc labelled saccharides and neo-glycoproteins for use as inhibitors, and reagents for covalent linkage to proteins and surfaces. The company was founded by Ulf Jörgen Nilsson and is headquartered in Lund, Sweden. | Miscellaneous Commercial Services | Director/Board Member Founder | |
Novo Ventures 1 A/S
 Novo Ventures 1 A/S Investment ManagersFinance Novo Ventures (Novo Ventures) is a venture capital operating division of Novo Nordisk Fonden. It engages in investment activities. The firm was established in 1999, and is headquartered in Hellerup, Denmark. | Investment Managers | Corporate Officer/Principal Corporate Officer/Principal | |
EpiTherapeutics ApS
 EpiTherapeutics ApS BiotechnologyHealth Technology EpiTherapeutics ApS is a holding company that develops cancer drugs based on research in the field of epigenetics. Its development programs are focused on enzymes involved in the regulation of transcription in cancer - current programs target histone demethylases and methyltransferases. The firm's regulation is commonly used for post-translational covalent modifications of histones and other chromatin-remodeling complexes, which determines whether a gene is accessible and hence, expressed or repressed. Its covalent modifications involved in epigenetic regulation include deoxyribonucleic acid methylation, histone acetylation, and histone methylation. The company was founded by Kristian Helin, Paul Andreas Compare Cloos, Jesper Aagaard Christensen, Karl Agger, and Klaus Hansen on September 18, 2008 and is headquartered in Greve, Denmark. | Biotechnology | Director/Board Member Corporate Officer/Principal Director/Board Member | |
Novo Seeds
 Novo Seeds Investment ManagersFinance Novo Seeds (Novo Seeds) is a venture capital operating division of Novo Nordisk Fonden. The firm was established in 2007, and is headquartered in Hellerup, Denmark. | Investment Managers | Private Equity Investor Director of Investments Director of Investments | |
| ASARINA PHARMA AB | Pharmaceuticals: Major | Director of Finance/CFO Chief Executive Officer | |
Pcovery ApS
 Pcovery ApS Pharmaceuticals: MajorHealth Technology Pcovery ApS develops drugs for treatment of invasive fungal infections. It discovers a new class of fungal therapy by targeting an essential and highly conserved component of the fungal cell membrane. The company was founded by Morten J. Buch-Pedersen, Michael Broberg Palmgren, Claus Olesen and Poul Nissen in 2009 and is headquartered in Copenhagen, Denmark. | Pharmaceuticals: Major | Chairman Director/Board Member | |
iSD Immunotech ApS
 iSD Immunotech ApS BiotechnologyHealth Technology iSD Immunotech ApS develops immunoregulatory peptides and proteins. It conducts research and development on immunoregulatory peptides for possible applications and commercialization. The company was founded by Peter Samuel Wulff, Shervin Bahrami, Finn Skou Pedersen, Mogens Ryttergård Duch, Lars Jørgen Østergaard, Martin Tolstrup, and Martin Thygesen on August 9, 2007 and is headquartered in Aarhus, Denmark. | Biotechnology | Director/Board Member Director/Board Member | |
| OBSEVA SA | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Forendo Pharma Oy
 Forendo Pharma Oy Pharmaceuticals: MajorHealth Technology Forendo Pharma Oy provides novel pharmaceutical treatments for endometriosis and low testosterone levels. Its product fispemifene is the first selective estrogen receptor modulator designed only for men, which helps for the treatment of symptoms of low testosterone, in phase II clinical studies in men with secondary hypogonadism; fispemifene has normalized the low testosterone levels. Its 17HSD1-inhibitor focuses on endometriosis, is a potent and selective lead compounds demonstrated in vivo proof of efficacy in disease model of endometriosis. The company was founded by Risto Arvo Sakari Lammintausta in 2013 and is headquartered in Turku, Finland. | Pharmaceuticals: Major | Chairman Director/Board Member | |
| RUBIUS THERAPEUTICS | Biotechnology | President Director/Board Member | |
IO Biotech ApS
 IO Biotech ApS BiotechnologyHealth Technology IO Biotech ApS operates as a clinical stage biotech company. It develops immunotherapy for cancer by targeting a mechanism used by tumour cells to evade immune responses. The company was founded by Mai-Britt Zocca, Mads Hald Andersen, Inge Marie Svane, Anders Ljungqvist and Per Thor Straten and is headquartered in Copenhagen, Denmark. | Biotechnology | Director/Board Member Director/Board Member Chief Executive Officer | |
Affinicon ApS
 Affinicon ApS Pharmaceuticals: MajorHealth Technology Affinicon ApS operates as a biotechnology company. It develops combinatory drugs for treatment of diseases such as inflammation, infections, and certain forms of cancer. The firm exploits a novel platform technology for targeted delivery of known drugs to macrophages. The company was founded by Niels Jonas Heilskov Graversen on July 4, 2013 and is headquartered in Aarhus, Denmark. | Pharmaceuticals: Major | Chairman Director/Board Member | |
ReViral Ltd.
 ReViral Ltd. BiotechnologyHealth Technology ReViral Ltd. specializes in the areas of virology and antiviral therapies. It offers drugs to treat respiratory synctial virus infection. The company was founded by Neil Matthews and Stuart Cockerill in 2011 and is headquartered in Stevenage, the United Kingdom. | Biotechnology | Director/Board Member Director/Board Member | |
| CYXONE AB | Pharmaceuticals: Major | Director/Board Member Chief Executive Officer | |
Fore Biotherapeutics, Inc.
 Fore Biotherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Fore Biotherapeutics, Inc. develops tumor specific driver mutations. It offers fully automated live-cell screening from NGS data. The company was founded by Haim Gil-Ad and Yoram Altschuler in 2011 and is headquartered in Philadelphia, PA. | Pharmaceuticals: Major | Director/Board Member Director/Board Member |
Statistiques
Internationale
| Danemark | 21 |
| Etats-Unis | 16 |
| Suède | 7 |
| Royaume-Uni | 3 |
| Suisse | 3 |
Sectorielle
| Health Technology | 30 |
| Consumer Services | 15 |
| Finance | 5 |
| Commercial Services | 3 |
| Miscellaneous | 2 |
Opérationnelle
| Director/Board Member | 370 |
| Corporate Officer/Principal | 121 |
| Independent Dir/Board Member | 73 |
| Chief Executive Officer | 69 |
| Chairman | 57 |
Relations les plus connectées
| Insiders | |
|---|---|
| Gunnar Magnus Modee Persson | 51 |
| Ernest Mario | 44 |
| Søren Lemonius | 39 |
| Chau Khuong | 38 |
| Carl Samuel Goldfischer | 31 |
| Erez Chimovits | 30 |
| Nanna Liebach Lüneborg | 29 |
| Stephan Christgau | 29 |
| Amit Munshi | 26 |
| James Sulat | 23 |
| Chandra Paul Leo | 22 |
| Søren Møller | 21 |
| Peter Nordkild | 20 |
| Ruchita Sinha | 18 |
| Karen Wagner | 17 |
- Bourse
- Insiders
- Hans Schambye
- Connexions Sociétés
